The strong Q2 beat and raised guidance confirm accelerating commercial adoption of AUCATZYL. The gross margin inflection and new credit facility remove near-term financing overhang. Watch for continued revenue growth trajectory and pipeline catalysts: CARLYSLE SLE data by year-end 2026 and BOBCAT MS data in Q1 2027.
Price Chart
Executive Summary
Autolus Therapeutics reported Q2 2026 AUCATZYL net product revenue of $45.7M, up 119% YoY, and raised FY 2026 guidance to $140-150M from $120-135M. Gross margin surged to 55% from 6% in Q1 2026, driven by volume growth and cost initiatives. The company also secured a $250M credit facility with Perceptive Advisors, with $75M funded at close, extending cash runway into Q2 2028. Net loss per share of $(0.15) beat consensus of $(0.19) by 21%. The combination of accelerating commercial execution, margin inflection, and strengthened balance sheet is a strong positive signal for a commercial-stage biotech.
Key Financial Metrics
Key Facts
- AUCATZYL net product revenue of $45.7M in Q2 2026, up 119% YoY and 74% QoQ from $26.2M in Q1 2026.
- FY 2026 net product revenue guidance raised to $140-150M from $120-135M.
- Gross margin improved to 55% in Q2 2026 from 6% in Q1 2026 and negative in all prior 2025 quarters.
- Entered into a $250M five-year, interest-only senior credit facility with Perceptive Advisors; $75M funded at close.
- Net loss per share of $(0.15) beat consensus of $(0.19) by 21% (19.6% beat).
- Cash, cash equivalents and marketable securities totaled $201.6M at June 30, 2026; cash runway extended into Q2 2028.
- 82 U.S. authorized treatment centers now operational.
- Workforce reduction of ~13% completed, expected to reduce operating expenses by ~$15M annually starting 2027.
Financial Impact
Q2 2026 product revenue $45.7M (vs $20.9M YoY); raised FY guidance by $20M at midpoint; gross margin inflection to 55% from negative; $250M credit facility secured.
Risk Factors
- Competition from other CD19 CAR-T therapies (e.g., Kymriah, Tecartus) in r/r B-ALL.
- Execution risk in expanding to new treatment centers and maintaining gross margin improvement.
- Pipeline data readouts (lupus nephritis, MS, pediatric ALL) are years away and carry binary risk.
- Dependence on single product AUCATZYL for near-term revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001730463-26-000119 |
| Document: autlex-991pr110826a01.htm | 0001730463-26-000119 |
| Document: autlex-992cp110826a01.htm | 0001730463-26-000119 |
| Document: 0001730463-26-000119-index-headers.html | 0001730463-26-000119 |
| Document: 0001730463-26-000119-index.html | 0001730463-26-000119 |
| Document: 0001730463-26-000119.txt | 0001730463-26-000119 |
| 8-K Data (Synthetic) | 0001730463-26-000119 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 12, 2026 20d ago | S-3 | $1.94 $1.94 | · 0.00% | ▼ −0.11% | $1.78 (−8.25%) |
Aug 11, 2026 7w ago | 8-K | $2.33 $2.29 | ▼ −1.72% | ▼ −1.31% | $1.78 (−23.61%) |
Aug 3, 2026 8w ago | 8-K | $1.82 $2.07 | ▲ +13.74% | ▲ +11.71% | $1.78 (−2.20%) |
Aug 3, 2026 8w ago | 8-K | $1.82 $2.07 | ▲ +13.74% | ▲ +11.71% | $1.78 (−2.20%) |
Jun 12, 2026 16w ago | Press Release | $1.56 $1.51 | ▼ −3.21% | ▼ −3.88% | $1.78 (+14.10%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.56 $1.53 | ▲ +1.92% | ▲ +2.36% | $1.78 (−14.10%) |
Jun 9, 2026 16w ago | 8-K | $1.46 $1.50 | ▼ −2.74% | ▼ −0.33% | $1.78 (−21.92%) |
May 21, 2026 19w ago | Press Release | $1.70 $1.84 | ▲ +8.24% | ▲ +6.58% | $1.78 (+4.71%) |
May 14, 2026 20w ago | 8-K | $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.78 (+11.95%) |
May 14, 2026 20w ago | Press Release | $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.78 (+11.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access